

L12 ANSWER 7 OF 35 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1998044129 PCTFULL ED 20020514
 TITLE (ENGLISH): ENHANCEMENT OF IMMUNE RESPONSE USING TARGETING
 MOLECULES
 TITLE (FRENCH): AMELIORATION DE LA REACTION IMMUNE AU MOYEN DE
 MOLECULES DE CIBLAGE
 INVENTOR(S): BOYLE, Jefferey, Stephen; BRADY, Jamie, Louise; LEW,
 Andrew, Mark
 PATENT ASSIGNEE(S): THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL
 RESEARCH; COMMONWEALTH SCIENTIFIC AND INDUSTRIAL
 RESEARCH ORGANISATION; THE UNIVERSITY OF MELBOURNE;
 THE
 WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH;
 CSL LIMITED; BOYLE, Jefferey, Stephen; BRADY, Jamie,
 Louise; LEW, Andrew, Mark
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9844129	A1	19981008
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE	
	ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC	
	LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU	
	SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH	
	GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT	
	BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ	
	CF CG CI CM GA GN ML MR NE SN TD TG	
APPLICATION INFO.:	WO 1998-AU208	A 19980326
PRIORITY INFO.:	AU 1997-PO 5891	19970327
	AU 1998-PP 1830	19980213
PI	WO 9844129	A1 19981008

I. M.

L12 ANSWER 22 OF 35 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1995031483 PCTFULL ED 20020514
 TITLE (ENGLISH): IMPROVEMENTS IN OR RELATING TO PEPTIDE DELIVERY
 TITLE (FRENCH): ADMINISTRATION AMELIOREE DE PEPTIDES
 INVENTOR(S): CARDY, Donald, Leonard, Nicholas; CARR, Frank, Joseph
 PATENT ASSIGNEE(S): ECLAGEN LIMITED; CARDY, Donald, Leonard, Nicholas;
 CARR, Frank, Joseph
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

	WO 9531483	A1 19951123
DESIGNATED STATES	AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG	
APPLICATION INFO.:	WO 1995-GB1107	A 19950515
PRIORITY INFO.:	GB 1994-9409643.5	19940513
	GB 1994-9417461.2	19940831
PI	WO 9531483	A1 19951123

L12 ANSWER 28 OF 35 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1993022332 PCTFULL ED 20020513
 TITLE (ENGLISH): RECOMBINANT PRODUCTION OF IMMUNOGLOBULIN-LIKE DOMAINS
 IN PROKARYOTIC CELLS
 TITLE (FRENCH): PRODUCTION RECOMBINANTE DE DOMAINES SEMBLABLES A
 L'IMMUNOGLOBULINE DANS DES CELLULES PROCARYOTES
 INVENTOR(S): WARD, Elizabeth, Sally; KIM, Jin-Kyoo
 PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM;
 WARD,
 Elizabeth, Sally; KIM, Jin-Kyoo
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

	WO 9322332	A2 19931111
DESIGNATED STATES	AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US US VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG	
APPLICATION INFO.:	WO 1993-US3895	A 19930426
PRIORITY INFO.:	US 1992-7/873,930	19920424
	US 1992-7/963,333	19921019

PI WO 9322332 A2 19931111
 ABEN Disclosed are recombinant vectors encoding immunoglobulin-like domains
 and portions thereof,
 such as T-cell variable domains, antidoby **Fc**-hinge fragments,
 subfragments and mutant domains with
 reduced biological half lives. Methods of producing large quantities of
 such domains, heterodimers,
 and. . . are single chain T-cell receptors, which are folded into
 beta-pleated sheet structures
 similar to those of immunoglobulin variable domains; antibody **Fc**
 and **Fc**-hinge domains, which have
 the same in vivo stability as intact antibodies; and domains engineered
 to have reduced in vivo half. . . and protein domains will be useful
 as templates for in vitro mutagenesis
 and high resolution structural studies; for immunization and
vaccination; and for the production of
 recombinant antibodies or chimaeric proteins with increased or
 decreased
 stability and longevity for
 therapeutic and. . .
 ABFR . . . a

intravenous

L12 ANSWER 34 OF 35 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1989012458 PCTFULL ED 20020513
 TITLE (ENGLISH): HETEROFUNCTIONAL CELLULAR IMMUNOLOGICAL REAGENTS,
 VACCINES CONTAINING SAME AND METHODS FOR THE USE OF
 SAME
 TITLE (FRENCH): REACTIFS IMMUNOLOGIQUES CELLULAIRES
 HETEROFONCTIONNELS,
 VACCINS LES CONTENANT ET LEURS MODES D'UTILISATION
 INVENTOR(S): ZIMMERMAN, Daniel, H.; ELLIOTT, Donald, A.
 PATENT ASSIGNEE(S): CELL MED, INC.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE

WO 8912458	A1	19891228
DESIGNATED STATES	AT AU BE CH DE FR GB IT JP LU NL SE	
APPLICATION INFO.:	WO 1989-US2503	A 19890612
PRIORITY INFO.:	US 1988-206,381	19880614
PI WO 8912458	A1	19891228

all modes

L12 ANSWER 23 OF 35 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1995010302 PCTFULL ED 20020514
 TITLE (ENGLISH): CELLULAR AND SERUM PROTEIN ANCHORS AND CONJUGATES
 TITLE (FRENCH): PROTEINE SERIQUE ET CELLULAIRE D'ANCRAGE ET CONJUGUES
 INVENTOR(S): POULETTY, Philippe; POULETTY, Christine
 PATENT ASSIGNEE(S): REDCELL, INC.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE

	WO 9510302	A1 19950420	
DESIGNATED STATES	AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1994-US10547	A	19940916
PRIORITY INFO.:	US 1993-8/137,821		19931015
	US 1994-8/237,346		19940503

PI WO 9510302 A1 19950420
 ABEN . . . target in a mammalian host, such as a toxin, drug of abuse, microbe, autoreactive immune cell, infected or tumorous cell, **antigen presenting** cell, or the like, joined to a second binding member specific for along-lived blood component, including cells, such as an.

DETD . . . for
 cardiovascular diseases, immunoglobulins such as total IgE for anaphylaxy, specific anti-allergen IgE, auto or allo-antibodies for autoimmunity or allo- or xenoimmunity, Ig **Fc** receptors or **Fc** receptor binding factors, carbohydrates (gal), natural antibodies involved in allo- or xenorejection, erythropoietin, angiogenesis factors, adhesion molecules, MIF, MAFj complement factors (classical. . . therapeutic dosage monitoring, treatments for overdosage of drugs or drugs of abuse, or the like. Also, the subject invention may be used to **vaccinate** against a pathogen or other deleterious entity, where various unicellular microorganisms and viruses have been described above. In addition, the subject invention can be employed to activate T cells toward particular targets, by providing for appropriate targets for **antigen presenting** cells, which will then present to the T cells or providing for direct activation of T cells
 The choice of the long-lived blood. . .

*intramuscular
 Sub-Q*

L12 ANSWER 19 OF 35 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1996040789 PCTFULL ED 20020514
 TITLE (ENGLISH): THERAPEUTIC COMPOUNDS COMPRISED OF ANTI-Fc RECEPTOR
 ANTIBODIES
 TITLE (FRENCH): COMPOSES THERAPEUTIQUES CONSTITUES D'ANTICORPS
 ANTI-RECEPTEURS FC
 INVENTOR(S): DEO, Yashwant, M.; GOLDSTEIN, Joel; GRAZIANO, Robert;
 SOMASUNDARAM, Chezian
 PATENT ASSIGNEE(S): MEDAREX, INC.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

	WO 9640789	A1 19961219
DESIGNATED STATES	AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG	
APPLICATION INFO.:	WO 1996-US9988	A 19960607
PRIORITY INFO.:	US 1995-8/484,172	19950607
PI	WO 9640789	A1 19961219

Sub Q, IV

L12 ANSWER 18 OF 35 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1997005886 PCTFULL ED 20020514
TITLE (ENGLISH): COMPOSITIONS FOR CONFERRING IMMUNOGENICITY TO A
PEPTIDE
TITLE (FRENCH): COMPOSITIONS CONFERANT UNE IMMUNOGENICITE A UN PEPTIDE
INVENTOR(S): STANTON, G., John; HUGHES, Thomas, K., Jr.; SMITH,
Eric, M.
PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9705886	A1	19970220
DESIGNATED STATES	AU CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL		
	PT SE		
APPLICATION INFO.:	WO 1996=US12632	A	19960805
PRIORITY INFO.:	US 1995-8/511,662		19950804
PI	WO 9705886	A1	19970220

DETD

Sub Q ; intramuscular

L14 ANSWER 1 OF 26

ACCESSION NUMBER:

TITLE (ENGLISH):

TITLE (FRENCH):

INVENTOR(S):

PATENT ASSIGNEE(S):

GRAZIANO,

LANGUAGE OF PUBL.:

DOCUMENT TYPE:

PATENT INFORMATION:

PCTFULL COPYRIGHT 2003 Univentio

1999028349 PCTFULL ED 20020515

CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS

CELLULES EXPRIMANT DES COMPOSANTS DE FIXANT AU

RECEPTEUR ANTI Fc

KELER, Tibor; GOLDSTEIN, Joel; GRAZIANO, Robert; DEO, Yashwant, M.

MEDAREX, INC.; KELER, Tibor; GOLDSTEIN, Joel;

Robert; DEO, Yashwant, M.

English

Patent

NUMBER

KIND

DATE

WO 9928349

A2 19990610

DESIGNATED STATES

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO
RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW
GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM
AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:

PRIORITY INFO.:

PI

WO 9928349

WO 1998-US25556

A 19981202

US 1997-60/067,232

19971202

A2 19990610

L14 ANSWER 10 OF 26 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1998002463 PCTFULL ED 20020514
 TITLE (ENGLISH): THERAPEUTIC MULTISPECIFIC COMPOUNDS COMPRISED OF
 ANTI-FC'alpha' RECEPTOR ANTIBODIES
 TITLE (FRENCH): COMPOSES THERAPEUTIQUES A SPECIFICITE MULTIPLE
 CONSISTANT EN ANTICORPS ANTI-RECEPTEURS DU FC'alpha'
 INVENTOR(S): DEO, Yashwant, M.; GRAZIANO, Robert; KELER, Tibor
 PATENT ASSIGNEE(S): MEDAREX, INC.; DEO, Yashwant, M.; GRAZIANO, Robert;
 KELER, Tibor
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

	WO 9802463	A1 19980122
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG	
APPLICATION INFO.:	WO 1997-US12013	A 19970710
PRIORITY INFO.:	US 1996-8/678,194	19960711
PI	WO 9802463	A1 19980122

L12 ANSWER 8 OF 35 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1998035684 PCTFULL ED 20020514
 TITLE (ENGLISH): METHODS FOR DETECTION OF KAPOSI'S SARCOMA-ASSOCIATED
 HERPESVIRUS-LIKE VIRUS
 TITLE (FRENCH): METHODES DE DETECTION D'UN VIRUS SEMBLABLE A
 L'HERPESVIRUS ASSOCIE AU SARCOME DE KAPOSI
 INVENTOR(S): BERENSON, James, R.; RETTIG, Matthew, B.; VESCIO,
 Robert, A.
 PATENT ASSIGNEE(S): BERENSON, James, R.; RETTIG, Matthew, B.; VESCIO,
 Robert, A.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9835684	A2	19980820
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US2820	A	19980212
PRIORITY INFO.:	US 1997-8/800,710		19970214
	US 1997-8/967,504		19971111
PI	WO 9835684	A2	19980820

I. V.

L12 ANSWER 16 OF 35 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1997030089 PCTFULL ED 20020514
TITLE (ENGLISH): NOVEL ANTIBODY-CYTOKINE FUSION PROTEIN, AND METHODS OF
MAKING AND USING THE SAME
TITLE (FRENCH): NOUVELLE PROTEINE DE FUSION ANTICORPS-CYTOKINE ET
METHODES D'ELABORATION ET D'UTILISATION DE CETTE
PROTEINE
INVENTOR(S): HARVILL, Eric, T.; MORRISON, Sherie, L.
PATENT ASSIGNEE(S): HARVILL, Eric, T.; MORRISON, Sherie, L.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9730089	A1	19970821
DESIGNATED STATES	AU CA IL JP US AT BE CH DE DK ES FI FR GB GR IE IT LU		
	MC NL PT SE		
APPLICATION INFO.:	WO 1997-US1420	A	19970211
PRIORITY INFO.:	US 1996-60/011,569		19960213
PI	WO 9730089	A1	19970821

I.V.

L12 ANSWER 12 OF 35 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1998006749 PCTFULL ED 20020514
 TITLE (ENGLISH): SOLUBLE MONOVALENT AND MULTIVALENT MHC CLASS II FUSION
 PROTEINS, AND USES THEREFOR
 TITLE (FRENCH): PROTEINES DE FUSION DE CLASSE II DU CMH, SOLUBLES,
 MONOVALENTES OU POLYVALENTES, ET UTILISATIONS
 ASSOCIEES
 INVENTOR(S): WUCHERPFENNIG, Kai, W.; STROMINGER, Jack, L.
 PATENT ASSIGNEE(S): PRESIDENT AND FELLOWS OF HARVARD COLLEGE;
 WUCHERPFENNIG, Kai, W.; STROMINGER, Jack, L.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9806749	A2	19980219
DESIGNATED STATES	AU CA JP NZ US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1997-US14503	A	19970815
PRIORITY INFO.:	US 1996-60/024,077		19960816
PI	WO 9806749	A2	19980219

DETD . . . responses by binding peptides from foreign antigens in an
 intracellular
 processing compartment, and by presenting these peptides on the surface
 of **antigen presenting**
 cells, where they may be recognized by specialized T cell receptors
 (TCRs) (reviewed in
 Strominger and Wiley, 1995). For example, the MHC. . .
 . . .
 0 chain. MHC class II molecules bind peptides
 in an intracellular processing compartment and present these peptides
 on
 the surface of **antigen**
presenting cells to T cells. Peptides are bound in an extended
 conformation, as left-handed type II
 polyproline helices, The majority of bound. . .
 . . .
 or to tolerize an individual to a particular MHC-peptide complex. For
 example, the
 Class II MHC fusion proteins may be include **Fc** regions which
 activate the complement system
 and, thereby, cause the destruction of T cells to which they bind,
 Alternatively, the fusion
 proteins. . . other point which does not interfere with the binding
 of the MHC-peptide
 complex to T cell receptors (e.g., anywhere along an **Fc**
 domain). Such cytotoxic substances
 include, for example, genistein, ricin, diphtheria toxins, Pseudomonas
 toxins, and radioactive
 I 0 isotopes (e.g., 121I). High doses. . . II N4HC fusion protein of
 the invention can
 cause tolerization to the MHC-peptide complex, even when lower doses
 would cause
 sensitization (i.e., **vaccination** or immunization). When the
 goal is to tolerize an individual to an
 antigen which is normally presented by the subject's own. . .

I.V.

L12 ANSWER 3 OF 35

ACCESSION NUMBER:

TITLE (ENGLISH):

TITLE (FRENCH):

T

INVENTOR(S):

PATENT ASSIGNEE(S):

LANGUAGE OF PUBL.:

DOCUMENT TYPE:

PATENT INFORMATION:

PCTFULL COPYRIGHT 2003 Univentio

1999013095 PCTFULL ED 20020515

USE OF MULTIVALENT CHIMERIC PEPTIDE-LOADED, MHC/IG
MOLECULES TO DETECT, ACTIVATE OR SUPPRESS

ANTIGEN-SPECIFIC T CELL-DEPENDENT IMMUNE RESPONSES

UTILISATION DE MOLECULES POLYVALENTES DU TYPE COMPLEXE

MAJEUR D'HISTOCOMPATIBILITE (CMH)/IMMOGLOBULINE (IG)

CHARGEES EN PEPTIDES CHIMERES POUR DECELER, ACTIVER OU

SUPPRIMER LES REPONSES IMMUNES DEPENDANT DES CELLULES

SPECIFIQUES DE L'ANTIGENE

SCHNECK, Jonathan; PARDOLL, Drew; O'HERRIN, Sean, M.;

SLANSKY, Jill; GRETEN, Tim

THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE;

SCHNECK, Jonathan; PARDOLL, Drew; O'HERRIN, Sean, M.;

SLANSKY, Jill; GRETEN, Tim

English

Patent

NUMBER

KIND

DATE

WO 9913095

A2 19990318

DESIGNATED STATES

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH
GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:

PRIORITY INFO.:

WO 1998-US18909 A 19980911

US 1997-60/058,573 19970911

US 1998-60/082,538 19980421

PI

WO 9913095

A2 19990318

L12 ANSWER 5 OF 35 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1998047916 PCTFULL ED 20020514
 TITLE (ENGLISH): BIFUNCTIONAL POLYPEPTIDES FOR CELL-SPECIFIC VIRAL
 TARGETING
 TITLE (FRENCH): POLYPEPTIDES BIFONCTIONNELS UTILISES DANS LE CIBLAGE
 VIRAL SPECIFIQUE EN FONCTION DES CELLULES
 INVENTOR(S): YOUNG, John; SNITKOVSKY, Sophie
 PATENT ASSIGNEE(S): PRESIDENT AND FELLOWS OF HARVARD COLLEGE; YOUNG, John;
 SNITKOVSKY, Sophie
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9847916	A1	19981029
DESIGNATED STATES	AU CA JP NZ US AT BE CH CY DE DK ES FI FR GB GR IE IT		
	LU MC NL PT SE		
APPLICATION INFO.:	WO 1998-US7720	A	19980416
PRIORITY INFO.:	US 1997-08/844,359		19970418
PI	WO 9847916	A1	19981029

DETD . . . epithelial cell,
 fibroblast, smooth muscle cell, blood cell (including a
 hematopoietic cell, red blood cell, T-cell, B-cell,
 etc.), tumor cell, cardiac muscle cell, macrophage,
dendritic cell, neuronal cell (e.g., a glial cell or
 astrocyte), or pathogen-infected cell (e.g., those
 infected by bacteria, viruses, virusoids, parasites, or
 prions).
 . . .
 exist in the virus
 5 as it is found in nature. Examples of therapeutic
 proteins include antigens or immunogens such as a
 polyvalent **vaccine**, cytokines, tumor necrosis factor,
 interferons, interleukins, adenosine deaminase, insulin,
 T-cell receptors, soluble CD4, epidermal growth factor,
 human growth factor, blood factors, such as. . . ApoC,
 ApoAI, the LDL receptor, negative selection markers or
 suicide proteins, such as thymidine kinase (including
 the HSV, CMV, VZV TK), anti-angiogenic factors, **Fc**
 receptors, plasminogen activators, such as t-PA, u-PA
 and streptokinase, dopamine, MHC, tumor suppressor genes
 such as p53 and Rb, monoclonal antibodies or antigen
 binding. . .

CLMEN. . . the
 target cell is selected from the group consisting
 of epithelial cells, fibroblasts, smooth muscle
 cells, blood cells, tumor cells, cardiac muscle
 cells, macrophages, **dendritic** cells, neuronal
 cells, and pathogen-infected cells.

L12 ANSWER 25 OF 35 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1995000175 PCTFULL ED 20020514
 TITLE (ENGLISH): AGENT WITH INFLUENCES HYPERACTIVE IMMUNOLOGICAL
 EFFECTOR CELLS
 TITLE (FRENCH): AGENT PERMETTANT D'INFLUER SUR DES CELLULES
 EFFECTRICES
 IMMUNOLOGIQUES HYPERACTIVES
 INVENTOR(S): LESKOVAR, Peter
 PATENT ASSIGNEE(S): LESKOVAR, Peter
 LANGUAGE OF PUBL.: German
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9500175	A1	19950105
DESIGNATED STATES	US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1994-EP1992	A	19940619
PRIORITY INFO.:	DE 1993-P 43 20 878.9		19930623
	DE 1993-P 43 24 877.2		19930725
	DE 1994-P 44 11 956.9		19940407
PI	WO 9500175	A1	19950105

DETD Der fUer die Transplantat-Abstossung kritische Anstieg der HHC
 II-positiven **APCs** (Ilpassenger
 lymphocytes) in organtransplantat kann durch Zusatz von
 Anti-HLAe-DR-Hab

bzw. entsprechende Fab/F(abl)2-
 Untereinheit und/oder Ca-Kanalblocker (Verapatil, Nifedipin,
 Dilthiazem)
 verhindert werden,
 Eine weitere Verbesserung. . .

. . .
 Complement-Fak-
 tor)-Assoziat treten; hierdurch werden in vivo die Nakrophagen des
 Impflings noch stAerker vor den Suppres-
 sor-T-Zellen bevorzugt, weil das Assoziat durch **Fc**- und
 C-Rezeptoren auf Nakrophagen gebunden wird,
 (3) Zur weiteren VerstAerkung der Immunisierung durch
Vaccinepathogen wird der Zusatz von Patho-
 gen-spezifischen IgE und/oder Konjugaten aus Pathogen-spezifischen
 Fab/F(abl)2-Untereinheit von IgG/IgM plus

Fc-Fragment von (IgE beliebiger Spezifitaet) allein oder
 kombiniert mit IL-4 empfohlen,

(4) Es ist ratsam die erste Impfung (priming) mit Zusatz von. . .